Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.

Su YL, Huang SY, Kuo CW, Xiao LY, Lin CT, Chen YH, Chang LC, Kuo MC, Wu CC, Peng JM, Wu CL, Huang HY, Chien CY

DOI: 10.1136/jitc-2026-014770
Published: 2026 Jul 7
Container: Journal for immunotherapy of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2026-014770,
  title = {Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.},
  author = {Su YL and Huang SY and Kuo CW and Xiao LY and Lin CT and Chen YH and Chang LC and Kuo MC and Wu CC and Peng JM and Wu CL and Huang HY and Chien CY},
  year = {2026},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2026-014770},
  url = {https://doi.org/10.1136/jitc-2026-014770}
}

RIS

TY  - JOUR
TI  - Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.
AU  - Su YL
AU  - Huang SY
AU  - Kuo CW
AU  - Xiao LY
AU  - Lin CT
AU  - Chen YH
AU  - Chang LC
AU  - Kuo MC
AU  - Wu CC
AU  - Peng JM
AU  - Wu CL
AU  - Huang HY
AU  - Chien CY
PY  - 2026
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2026-014770
UR  - https://doi.org/10.1136/jitc-2026-014770
ER  -

APA

YL, S., SY, H., CW, K., LY, X., CT, L., YH, C., LC, C., MC, K., CC, W., JM, P., CL, W., HY, H., & CY, C. (2026). Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2026-014770

Source records

pubmed · retrieved 2026-11-10T10:41:30.589Z